Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exalgo Joint Advisory Committee Will Compare Risks To Other Opioids

This article was originally published in The Pink Sheet Daily

Executive Summary

Panel will decide whether to recommend a risk management program a la Onsolis or Embeda or something different altogether.

You may also be interested in...



Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead

FDA is reopening the public comment period for the class-wide opioid Risk Evaluation and Mitigation Strategy until Oct. 19, 2010.

Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead

FDA is reopening the public comment period for the class-wide opioid Risk Evaluation and Mitigation Strategy until Oct. 19, 2010.

Joint Advisory Committee Says Exalgo Should Have Phased-In Entry To Market

A joint advisory committee said Neuromed's extended-release hydromorphone, Exalgo, should get a phased roll-out, as was used with Purdue's now-withdrawn Palladone.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel